Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors

Product is added to your Wishlist
Global Biologics Drug Discovery Market

Global Biologics Drug Discovery Market Analysis and Forecast, (2017-2025) (Focus on Method/Phase, Product Type, Manufacturer Type and Competitive Landscape)

The global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is estimated to grow over $22.7 billion by 2025. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future.

SKU: BH029A
Published Year: 2017
 
 

The pharmaceutical Industry is a multibillion market consisting of innovator drugs & generics. The pharmaceutical market consists of a companies involved in the research, development, manufacturing and commercialization of drugs for human & animal use. Geographically, biologics have registered near double digit annual growth rate, whereas, the pharmaceutical drugs registered only single digit annual growth rate, in the past five years. This double digit growth was largely fuelled by the substantial investments of the major pharmaceutical companies, who realized the potential of the market quite early. Biologics are defined as pharmaceutical products obtained from living cells or micro-organisms. These are complex & large molecules consisting of proteins, peptides, nucleic acids, sugars, cellular structures or a combination of these.

The biologics drug discovery involves target identification, hit-to-lead stage, lead identification & optimization. Technologies used for the development of biologics include genomics, proteomics, microarrays, cell cultures, phage display technologies and monoclonal antibody technologies among others. The market analysis includes an in-depth examination of the key ecosystem players and key strategies & developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities and challenges) and industry analysis. 

The purpose of the study is to gain a holistic view of the biologics drug discovery market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the biologics drug discovery market. The market has been segmented into ‘product’, ‘method’, ‘manufacture’ and ‘geographical regions’. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global biologics drug discovery market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global biologics drug discovery market and assesses the factors governing the same.

The answers to the following key questions can be derived from this report:

•    What are the major market drivers, challenges and opportunities in the global biologics drug discovery market and their case studies?
•    How the biologics drug discovery market evolve and what did is its scope in the future?
•    What is the market share of the leading segments and sub-segments of the global biologics drug discovery market in 2016 and 2025?
•    How will each segment of the global biologics drug discovery market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2025?
•    What are the influencing factors that may affect the market share of the key players?
•    How will the industry evolve during the forecast period between 2016 and 2025?
•    What are the key developmental strategies implemented by the key players to stand out in this market?
•    What will be the growth rate of the outsourced manufacturing segment during the forecast period?
•    Who are the key outsourced manufacturers of the biologics drug discovery market market?
•    How the market has been segmented on the basis of phase/method? Which method is highly adopted in the biologics drug discovery process?
•    Which technologies have been covered in the Target Identification phase?
•    What will be the value of oncology biologics drug discovery segment by 2025?
•    Which geographical location will contribute to the highest sales of biologics?
•    In Europe, which country is dominating the biologics drug discovery market? Also, which country will show the highest growth rate?

The key players which have significant contributions to the biologics drug discovery market are Albany Molecular Research Inc., GenScript, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, AbbVie Inc., Amgen Inc., Lilly, Bristol-Myers Squibb, Novo Nordisk, Merck KGaA, Allergan, Plc, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., and Bayer AG, and Biocon Ltd. among others.

TABLE OF CONTENT
Executive Summary
1 Report Scope
1.1 Scope of the Report
1.2 Global Biologics Drug Discovery Market Segmentation
1.3 Key Learnings
1.4 Research Methodology
1.4.1. Data Triangulation
1.4.2. Key Data Points From Secondary Sources 
1.4.3. Key Data Points From Primary Sources 
1.4.4. Top-Down  Approach (Segmental Analysis)
1.4.5. Bottom-Up Approach (Segmental Analysis)
1.4.6. Assumptions and Limitations
1.4.7. Data and Prediction Modelling
2 Market Overview
2.1 Introduction
2.2 Market Dynamics
2.2.1. Market Drivers
2.2.2. Market Challenges
2.2.3. Market Opportunities
3 Industry Insights
3.1. Regulatory Scenario
3.2. Patent Landscape
4 Competitive Landscape
4.1 Share of Key Developments & Strategies
4.1.1. Collaboration/ Partnership/ Joint Venture/ Licensing Agreement
4.1.2. Mergers & Acquisitions
4.1.3. Business Expansion
4.1.4. Products/Platform/Services Launch
4.1.5. Others
4.2. Porter's Five Forces Analysis
4.2.1. Bargaining Power of Suppliers
4.2.2. Bargaining Power of Buyers
4.2.3. Threat of New Entrants>
4.2.4. Threat of Substitutes
4.2.5. Intensity of Competitive Rivalry 
5 Global Biologics Drug Discovery Market, by Product
5.1. Small Molecule Vs. Biologicals
5.2. Biologicals
5.2.1. Monoclonal Antibodies
5.2.2. Recombinant Proteins
5.2.3. Other biologics
6 Global Biologics Drug Discovery Market, by Phase
6.1. Target Identification/Validation
6.1.1. Functional Genomics/Proteomics
6.1.2. Computational Approach/In-silico
6.1.3. Cell based Assay
6.1.4. Knock out studies/CRISPR/Cas9
6.1.5. Animal/Disease Based Models
6.2. Hit Generation
6.3. Lead Identification
6.4. Lead Optimization
7 Global Biologics Drug Discovery Market, by Manufacture Type
7.1. Type of Manufacturing
7.1.1. In-House Manufacturing
7.1.2. Advantages of Outsourcing Development
7.1.3. Outsourced Manufacturing
8 Global Biologics Drug Discovery Market, by Geography
8.1. Introduction
8.2. North America
8.3. Europe
8.4. Asia-Pacific
8.5 Rest Of the World
9 Company Profiles
9.1. Abbvie Inc.
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Financials
9.1.3.1 Financial Summary
9.1.4. Abbvie Inc.: SWOT Analysis
9.2. Albany Molecular Research Inc.
9.2.1. Overview
9.2.2. Product/Services Portfolio
9.2.3. Financials
9.2.3.1 Financial Summary
9.2.4. Albany Molecular Research Inc.: SWOT Analysis
9.3. Allergan plc.
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Financials
9.3.3.1 Financial Summary
9.3.4. Allergan plc.: SWOT Analysis
9.4. Amgen Inc.
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Financials
9.4.3.1 Financial Summary
9.4.4. Amgen Inc.: SWOT Analysis
9.5. Aptuit
9.5.1. Overview
9.5.2. Product/Services Portfolio
9.5.3. Financials
9.5.3.1 Financial Summary
9.5.4. Amgen Inc.: SWOT Analysis
9.6. Atellas Pharma Inc.
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Financials
9.6.3.1. Financial Summary
9.6.4. Astellas Pharma Inc.: SWOT Analysis
9.7. AstraZeneca PLC
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Financials
9.7.3.1. Financial Summary
9.7.4. AstraZeneca Plc: SWOT Analysis
9.8. Bayer AG
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Financials
9.8.3.1. Financial Summary
9.8.4. Bayer AG: SWOT Analysis
9.9. Biocon Ltd.
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Financials
9.9.3.1. Financial Summary
9.9.4. Bayer AG: SWOT Analysis
9.10. Boehringer Ingelheim GmbH
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Financials
9.10.3.1. Financial Summary
9.10.4. Boehringer Ingelheim GmbH : SWOT Analysis
9.11. BRISTOL-MYERS SQUIBB COMPANY
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Financials
9.11.3.1. Financial Summary
9.11.4. BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
9.12. Charles River Laboratories International, Inc.
9.12.1. Overview
9.12.2. Product/Services Portfolio
9.12.3. Financials
9.12.3.1. Financial Summary
9.12.4. Charles River Laboratories International Inc: SWOT Analysis
9.13. Eli Lilly and Company
9.13.1. Overview
9.13.2. Products Portfolio
9.13.3. Financials
9.13.3.1. Financial Summary
9.13.4. Eli Lilly and Company: SWOT Analysis
9.14. Evotec AG
9.14.1. Overview
9.14.2. Product/Services Portfolio
9.14.3. Financials
9.14.3.1. Financial Summary
9.14.4. Evotec AG: SWOT Analysis
9.15. F. Hoffmann-La Roche AG 
9.15.1. Overview
9.15.2. Product Portfolio
9.15.3. Financials
9.15.3.1. Financial Summary
9.15.4. F. Hoffmann-La Roche AG: SWOT Analysis
9.16. GenScript
9.16.1. Overview
9.16.2. Product/Services Portfolio
9.16.3. Corporate Summary
9.16.4. GenScript: SWOT Analysis
9.17. Gilead Sciences Inc.
9.17.1. Overview
9.17.2. Product Portfolio
9.17.3. Financials
9.17.3.1. Financial Summary
9.17.4. Gilead Sciences Inc.: SWOT Analysis
9.18. GlaxoSmithKline Plc
9.18.1. Overview
9.18.2. Product Portfolio
9.18.3. Financials
9.18.3.1. Financial Summary
9.18.4. GlaxoSmithKline Plc: SWOT Analysis
9.19. JOHNSON & JOHNSON
9.19.1. Overview
9.19.2. Product Portfolio
9.19.3. Financials
9.19.3.1. Financial Summary
9.19.4. JOHNSON & JOHNSON: SWOT Analysis
9.20. Laboratory Corporation of America Holdings
9.20.1. Overview
9.20.2. Product/Services Portfolio
9.20.3. Financials
9.20.3.1. Financial Summary
9.20.4. Laboratory Corporation of America Holdings: SWOT Analysis
9.21. Merck KGaA
9.21.1. Overview
9.21.2. Product Portfolio
9.21.3. Financials
9.21.3.1. Financial Summary
9.21.4. Merck KGaA: SWOT Analysis
9.22. Merck & CO., Inc.
9.22.1. Overview
9.22.2. Product Portfolio
9.22.3. Financials
9.22.3.1. Financial Summary
9.22.4. Merck & CO., Inc.: SWOT Analysis
9.23. Novartis AG
9.23.1. Overview
9.23.2. Product Portfolio
9.23.3. Financials
9.23.3.1. Financial Summary
9.23.4. Novartis AG: SWOT Analysis
9.24. NOVO NORDISK
9.24.1. Overview
9.24.2. Product Portfolio
9.24.3. Financials
9.24.3.1. Financial Summary
9.24.4. NOVO NORDISK: SWOT Analysis
9.25. Pfizer Inc.
9.25.1. Overview
9.25.2. Product Portfolio
9.25.3. Financials
9.25.3.1. Financial Summary
9.25.4. Pfizer Inc.: SWOT Analysis
9.26. Sanofi
9.26.1. Overview
9.26.2. Product Portfolio
9.26.3. Financials
9.26.3.1. Financial Summary
9.26.4. Sanofi: SWOT Analysis
9.27. Teva Pharmaceuticals
9.27.1. Overview
9.27.2. Product Portfolio
9.27.3. Financials
9.27.3.1. Financial Summary
9.27.4. Teva Pharmaceuticals: SWOT Analysis
9.28. WuXi Apptec
9.28.1. Overview
9.28.2. Product/Services Portfolio
9.28.3. Corporate Summary
9.28.4. WuXi Apptec: SWOT Analysis
List of Tables
1 Global Biologics Drug Discovery Market (2016 & 2023)
2 Drug Approvals by FDA
3 Percentage of total regional population aged 65 years & above: 2015 & 2030
4 Regulatory Scenario across the world
5 Patent Landscape
6 Partnership/Collaboration/Joint Ventures/Licensing Agreements
7 Mergers & Acquisitions
8 Business Expansion
9 Products/Platform/Services Launch
10 Other-Funding, Milestones, Awards
11 Factors Affecting Bargaining Power of Suppliers
12 Factors Affecting the Bargaining Power of Buyers
13 Factors Affecting Threat of New Entrant
14 Factors Affecting the Threat of Substitutes
15 Factors Affecting the Intensity of Competitive Rivalry
16 Difference between Small Molecule and Biologics
17 Examples of marketed biological products.
18 Some of the marketed products with cells used
19 Some of the biologics drugs in different phases of development
20 Percentage of population aged 60 years or above
21 Percentages of population aged 60 or over.
22 Overview: AbbVie Inc.
23 Overview: Albany Molecular Research Inc.
24 Overview: Allergan plc.
25 Overview: Amgen Inc.
26 Overview: Aptuit
27 Overview: Astellas Pharma Inc. 
28 Overview: AstraZeneca PLC
29 Overview: Bayer AG
30 Overview: Biocon Ltd.
31 Overview: Boehringer Ingelheim GmbH
32 Overview: BRISTOL-MYERS SQUIBB COMPANY
33 Overview: Charles River Laboratories International, Inc.
34 Overview: Eli Lilly and Company
35 Overview: Evotec AG
36 Overview: F. Hoffmann-La Roche AG 
37 Overview: GenScript
38 Overview: GILEAD SCIENCES, INC.
39 Overview: GlaxoSmithKline Plc
40 Overview: JOHNSON & JOHNSON
41 Overview: Laboratory Corporation of America Holdings
42 Overview: Merck KGaA
43 Overview: Merck & CO., Inc.
44 Overview: Novartis AG
45 Overview: NOVO NORDISK
46 Overview: Pfizer Inc.
47 Overview: Sanofi
48 Overview: Teva Pharmaceuticals Industries Limited
49 Overview: WuXi Apptec
List of Figures
1 Global Biologics Drug Discovery Market Value, 2015-2025 ($Million)
2 Global Drug Discovery Market Value, 2015-2025 ($Million)
3 Global Biologics Drug Discovery Market, 2016-2025 ($Million), by phase
4 Global Biologic Drug Discovery Market by Manufacture Type, 2016
5 Global Biologic Drug Discovery Market by Manufacture Type, 2025
6 Global Biologics Drug Discovery Market, by Product Type, 2016
7 Global Biologics Drug Discovery Market, by Product Type, 2025
8 Global Biologics Drug Discovery Market Value by Geography, 2016 & 2025 ($Million)
9 Global Biologics Drug Discovery Market, by Geography, 2016
10 Global Biologics Drug Discovery Market, by Geography, 2025
11 Global Biologics Drug Discovery Market Segmentation
12 Research Methodology
13 Data Triangulation
14 Key Data Points From Secondary Sources 
15 Key Data Points From Primary Sources 
16 Top-Down  Approach (Segmental Analysis)
17 Bottom-Up Approach (Segmental Analysis)
18 Assumptions and Limitations
19 Drug Discovery of Biologics
20 Share of Key Development & Strategies
21 Porter’s Five Forces Analysis
22 Drug Market by product type, 2016-2023 (in $Million)
23 Hybridoma technique of monoclonal antibody production
24 Methods of Humanization of Antibodies 
25 Monoclonal Antibody Drug Discovery Market by product type, 2016-2025 (in $million)
26 Global monoclonal antibody target identification market, 2016-2025 (in $million)
27 Global monoclonal antibody hit generation/validation market, 2016-2025 (in $million)
28 Global monoclonal antibody lead identification market, 2016-2025 (in $million)
29 Global monoclonal antibody lead optimization market, 2016-2025 (in $million)
30 Factors affecting choice of cells
31 Recombinant Proteins Drug Discovery Market by method type, 2016-2025 (in $Million)
32 Global recombinant protein target identification market, 2016-2025 (in $million)
33 Global recombinant protein hit generation/validation market, 2016-2025 (in $million)
34 Global recombinant protein lead identification market, 2016-2025 (in $million)
35 Global recombinant protein lead optimization market, 2016-2025 (in $million)
36 Global Biologics Drug Discovery Market, by phase, 2016-2025 (in $million)
37 Characteristics of a Disease Model
38 Global Biologics Drug Discovery Market, by phase, 2016-2025 (in $million)
39 Methods for Hybridoma Screening
40 Global Biologics Drug Discovery Market, Hit Generation, 2016-2025 (in $million)
41 Global Biologics Drug Discovery Market, Lead Identification, 2016-2025 (in $million)
42 Methods for humanization of antibodies
43 Global Biologics Drug Discovery Market,  Lead Optimization, 2016-2025 (in $million)
44 Examples of Some of The Pharmaceutical Companies
45 Examples of Some of The Contract Research Organisations
46 Drug Market by manufacture type, 2016-2023 (in $million)
47 Global Biologics Drug Discovery Market, By Geography 
48 Global Biologics Drug Discovery Market, 2016-2025, by geography (in $Million)
49 Global Biologics Drug Discovery Market, 2016-2025, North America (in $Million)
50 Global Biologics Drug Discovery Market, 2016-2025, North America, by Manufacture Type (in $Million)
51 The U.S. Biologics Drug Discovery Market Value, 2016-2025 ($Million)
52 Canada Biologics Drug Discovery Market Value, 2016-2025 ($Million)
53 Global Biologics Drug Discovery Market, 2016-2025, Europe (in $Million)
54 Global Biologics Drug Discovery Market, 2016-2025, Europe, by Manufacture Type (in $Million)
55 Germany Biologics Drug Discovery Market Value, 2016-2025 ($Million)
56 The U.K. Biologics Drug Discovery Market Value, 2016-2025 ($Million)
57 France Biologics Drug Discovery Market Value, 2016-2025 ($Million)
58 Switzerland Biologics Drug Discovery Market Value, 2016-2025 ($Million)
59 Rest of Europe Biologics Drug Discovery Market Value, 2016-2025 ($Million)
60 Global Biologics Drug Discovery Market, 2016-2025, Asia Pacific (in $Million)
61 Global Biologics Drug Discovery Market, 2016-2025, Asia Pacific, by Manufacture Type (in $Million)
62 Japan Biologics Drug Discovery Market Value, 2016-2025 ($Million)
63 China Biologics Drug Discovery Market Value, 2016-2025 ($Million)
64 India Biologics Drug Discovery Market Value, 2016-2025 ($Million)
65 Australia Biologics Drug Discovery Market Value, 2016-2025 ($Million)
66 Rest of Asia Pacific Biologics Drug Discovery Market Value, 2016-2025 ($Million)
67 AbbVie Inc.: Product Portfolio
68 AbbVie Inc. : Overall Financials (2014-2016)
69 AbbVie Inc.:  Net Sales by Geographic Destination (2014-2016)
70 AbbVie Inc. : SWOT Analysis
71 Albany Molecular Research Inc.: Product/ Services Portfolio
72 Albany Molecular Research Inc.: Overall Financials
73 Albany Molecular Research Inc.: Net revenue by company segment
74 Albany Molecular Research Inc.: Contract Revenue by Geography
75 Albany Molecular Research Inc: SWOT Analysis
76 Allergan plc.: Product Portfolio
77 Allergan plc: Overall Financials (2014-2016)
78 Allergan plc: Net Sales by Business Segments (2015-2016)
79 Allergan plc: Net Sales by Business Segment (2014)
80 Allergan plc: SWOT Analysis
81 Amgen Inc.: Product Portfolio
82 Amgen Inc. : Overall Financials (2014-2016)
83 Amgen Inc. :  Net Sales by Geographic Destination (2014-2016)
84 Amgen Inc. : SWOT Analysis
85 Aptuit: Product/Services Portfolio
86 Aptuit: SWOT Analysis
87 Astellas Pharma Inc.: Product Portfolio
88 Astellas Pharma Inc. : Overall Financials (2014-2016)
89 Astellas Pharma Inc. : Net Sales by Product Type (2014-2016)
90 Astellas Pharma Inc.  : Net Sales by Geographic Destination (2014-2016)
91 Astellas Pharma Inc. : SWOT Analysis
92 AstraZeneca PLC: Product Portfolio
93 AstraZeneca PLC : Overall Financials, 2014-2016
94 AstraZeneca PLC : Net Revenue by Business Segment, 2014-2016
95 AstraZeneca PLC : Revenue across Different Geographies, 2014-2016
96 AstraZeneca PLC: SWOT Analysis
97 Bayer AG: Product Portfolio
98 Bayer AG : Overall Financials, 2014-2016
99 Bayer AG : Net Revenue by Business Segment, 2014-2016
100 Bayer AG: Net Revenue by Geographic Destination, 2014-2016
101 Bayer AG: SWOT Analysis
102 Biocon Ltd.: Product Portfolio
103 Biocon Ltd.: Overall Financials, 2015-2017
104 Biocon Ltd.: Net Revenue by Business Segment, 2015-2017
105 Biocon Ltd.: Net Revenue by Pharma Business Segment, 2014-2016
106 Biocon Ltd.: Revenue across Different Geographies, 2014-2016
107 Biocon Ltd.: SWOT Analysis
108 Boehringer Ingelheim GmbH : Product Portfolio
109 Boehringer Ingelheim GmbH : Overall Financials (2014-2016)
110 Boehringer Ingelheim GmbH : Net Sales by Product Type (2014-2016)
111 Boehringer Ingelheim GmbH : Net Sales by Geographic Destination (2014-2016)
112 Boehringer Ingelheim GmbH: SWOT Analysis
113 BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio
114 BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2016)
115 BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Product Type (2014-2016)
116 BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Geographic Destination (2014-2016)
117 BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
118 Charles River Laboratories: Product/Services Portfolio
119 Charles River Laboratories: Overall Financials
120 Charles River Laboratories: Net sales by product segment
121 Charles River Laboratories: Net sales by Geography
122 Charles River Laboratories: SWOT Analysis
123 Eli Lilly and Company: Product Portfolio
124 Eli Lilly and Company : Overall Financials (2014-2016)
125 Eli Lilly and Company : Net Sales by Product Type (2014-2016)
126 Eli Lilly and Company : Net Sales by Geographic Destination (2014-2016)
127 Eli Lilly and Company: SWOT Analysis
128 Evotec AG: Product/Services Portfolio
129 Evotec AG : Overall Financials (2014-2016) 
130 Evotec AG : Net Revenue by Business Segment
131 Evotec AG : Net Revenue by Region (2014-2016)
132 Evotec: SWOT Analysis
133 Roche AG: Product Portfolio
134 Roche AG: Overall Financials, (2013–2016)
135 Roche AG: Revenue across Different Geographies, 
136 Roche AG: Net Revenue by Business Segment, (2013-2016)
137 Roche AG: SWOT Analysis
138 GenScript: Product/Services Portfolio
139 GenScript: SWOT Analysis
140 GILEAD SCIENCES, INC. : Product Portfolio
141 GILEAD SCIENCES, INC. : Overall Financials (2014-2016)
142 GILEAD SCIENCES, INC. : Net Sales by Geographic Destination (2014-2016)
143 GILEAD SCIENCES, INC. : SWOT Analysis
144 GSK: Product Portfolio
145 GSK: Overall Financials (2013-2016)
146 GSK: Net Revenue by Business Segments (2013-2016)
147 GSK: Net Revenue by Geography (2013-2015)
148 GSK: Net Revenue by Geography (2016)
149 GlaxoSmithKline Plc: SWOT Analysis
150 JOHNSON & JOHNSON: Product Portfolio
151 JOHNSON & JOHNSON: Overall Financials (2014-2016) 
152 JOHNSON & JOHNSON : Net Revenue by Business Segment
153 JOHNSON & JOHNSON : Net Revenue by Region (2014-2016)
154 JOHNSON & JOHNSON: SWOT Analysis
155 Laboratory Corporation of America Holdings: Product/Services Portfolio
156 Laboratory Corporation of America Holdings: Overall Financials
157 Laboratory Corporation of America Holdings: Net sales by services segment
158 Laboratory Corporation of America Holdings: Net sales by Geography
159 Laboratory Corporation of America Holdings : SWOT Analysis
160 Merck & CO., Inc. KGaA: Overall Financials, (2014-2016)
161 Merck & CO., Inc. KGaA: Net Revenue by Business Segments, (2014-2016)
162 Merck & CO., Inc. KGaA: Net Revenue by Geography, (2014)
163 Merck & CO., Inc. KGaA: Net Revenue by Geography, (2015-2016)
164 Merck KGaA : SWOT Analysis
165 Merck & CO., Inc.: Product Portfolio
166 Merck & CO., Inc.: Overall Financials (2013-2016)
167 Merck & CO., Inc.: Net Revenue by Business Segments (2013-2014)
168 Merck & CO., Inc.: Net Revenue by Business Segments (2015-2016)
169 Merck & CO., Inc.: Net Revenue by Geography (2013-2014)
170 Merck & CO., Inc.: Net Revenue by Geography (2015-2016)
171 Merck & Co., Inc. : SWOT Analysis
172 Novartis: Product Portfolio
173 Novartis: Overall Financials (2013-2016)
174 Novartis: Net Revenue by Geography 
175 Novartis: Net Revenue by Business Segments 
176 Novartis: Net Revenue by Business Segments (2015-2016)
177 Novartis AG: SWOT Analysis
178 Novo Nordisk: Product Portfolio
179 Novo Nordisk: Overall Financials, 2014-2016
180 Novo Nordisk: Net Revenue by Business Segment, 2014-2016
181 Novo Nordisk: Revenue across Different Geographies, 2014-2016
182 NOVO Nordisk: SWOT Analysis
183 Pfizer: Product Portfolio
184 Pfizer: Overall Financials (2013-2016)
185 Pfizer: Net Revenue by Geography (2013-2016)
186 Pfizer: Net Revenue by Business Segments (2013-2014)
187 Pfizer: Net Revenue by Business Segments (2015-2016)
188 Pfizer Inc. : SWOT Analysis
189 Sanofi: Product Portfolio
190 Sanofi: Overall Financials (2014-2016)
191 Sanofi: Net Sales by Business Segments (2014-2016)
192 Sanofi: Net Sales by Geographic Destination (2014-2016)
193 Sanofi: Net Sales by Franchise (2014-2016)
194 Sanofi: SWOT Analysis
195 Teva Pharmaceutical Industries Limited: Product Portfolio
196 Teva Pharmaceutical Industries Limited: Overall Financials, (2013-2016)
197 Teva Pharmaceutical Industries Limited : Net Revenue by Business Segments, (2013-2016)
198 Teva Pharmaceutical Industries Limited: Net Revenue by Geography, (2013-2016)
199 Teva Pharmaceutical Industries Ltd.: SWOT Analysis
200 WuXi Apptec: Product/Services Portfolio
201 WuXi Apptec: SWOT Analysis

The introduction of biologic therapies gave a new ray of hope for people suffering from chronic inflammatory diseases. Biologics effected their life not only by reducing dependency on health and welfare systems but also by improving their physical function to live independently. The entry of biosimilars makes these effective therapies more affordable, though the concern of after effects still exists. 

The purpose of the study is to gain a holistic view of the biologics drug discovery market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the biologics drug discovery market. The market has been segmented into ‘product’, ‘method’, ‘manufacture’ and ‘geographical regions’. 

The global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is estimated to grow over $22.7 billion by 2025. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future. Moreover, ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories in the development of novel therapeutic biologic drugs.

The global biologics drug discovery market can be segmented based on the basis of phase of discovery into target identification, hit generation, lead identification & lead optimization. The major contributor towards the market in 2016 was the lead optimization phase. Based on the manufacture type, the market is segmented into in-house & outsourced. The in-house market for the global biologics drug discovery was estimated to be $6.5 billion in 2016. The CAGR was highest for the out-sourced manufacturing. 

Moreover, based on the product type, monoclonal antibody is anticipated to be the major contributor to the market. The market for the drug discovery of monoclonal antibody is expected to reach $10.7 billion by 2025. The next contributing segment is recombinant proteins. Geographically, the largest contributor to the growth of the global biologics drug discovery market was found to be North America due to the presence of pharmaceutical companies involved in R&D of biologics. This was followed by Europe. The fastest growing region was Asia-pacific due to the increasing presence of Contract Research Organisations (CRO).

Biologics are expected to contribute 50% to the sales of the top 100 products during the forecast period. This will lead to increased investment in the global biologics drug discovery market in future. For instance, in 2016, among the most valued R&D projects were Roche’ Ocrelizumab & Sanofi’s Dupilumab. And in 2017, Ocrevus (Ocrelizumab) & Dupixient (dupilumab) were among the top 2 product launches so far. 

The biologics market presents with opportunities to change the treatment options. The development of antibody drug conjugates, glycosylated antibodies, Chimeric Antigen Receptor-T (CAR-T) cell therapy and bio-betters presents opportunities for the further growth of the biologics drug discovery market. 

The report provides in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each. Some of the key players are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Gilead Sciences, Inc., AbbVie Inc., Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb GmbH, Novo Nordisk, Merck KGaA and Allergan, Plc.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields

OUR HAPPY CLIENTS


related reports

 

OUR CLIENTS